港股异动丨康宁杰瑞暴涨30%,旗下产品获药监局认定为突破性疗法

格隆汇
18 Mar
康宁杰瑞-B(9966.HK)盘中飙升超30%,报7.59港元,股价创2023年11月以来新高。集团公布,旗下药物JSKN003,获得国家药品监督管理局审评中心认定为突破性疗法,用于治疗铂耐药复发性上皮性卵巢癌、原发性腹膜癌或输卵管癌。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10